A Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions
Lori J. Wirth(Massachusetts General Hospital), Monica M. Bertagnolli(National Institutes of Health), Megan Othus(Cancer Research And Biostatistics), Laura A. Goguen(Brigham and Women's Hospital), Charles M. Norris, Jeffrey F. Krane(University of California, Los Angeles), Robert I. Haddad(Georgetown University), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Yi Li(Nanyang Technological University), David M. Dorfman(Brigham and Women's Hospital), Amy E. Moran(Oregon Health & Science University)
Cited by 29
Related Papers
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k